Recent Quotes (30 days)

You have no recent quotes
chg | %

Critical Outcome Technologies Inc.  

(Public, CVE:COT)   Watch this stock  
Find more results for COT
0.000 (0.00%)
Delayed:   3:59PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.19 - 0.38
Open     -
Vol / Avg. 0.00/85,387.00
Mkt cap 37.94M
P/E     -
Div/yield     -
EPS -0.04
Shares 126.47M
Beta 0.51
Inst. own     -
Sep 29, 2015
Q1 2016 Critical Outcome Technologies Inc Earnings Release
Sep 17, 2015
Critical Outcome Technologies Inc at EBD Group BioPharm America
Sep 10, 2015
Critical Outcome Technologies Inc at Rodman & Renshaw Global Investment Conference
Aug 28, 2015
Q4 2015 Critical Outcome Technologies Inc Earnings Release

Key stats and ratios

Q3 (Jul '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -97.92% -126.67%
Return on average equity -183.93% -251.35%
Employees 10 -
CDP Score - -


213 - 700 Collip Circle
+1-519-8585157 (Phone)
+1-519-8585179 (Fax)

Website links


Critical Outcome Technologies Inc. (COTI) is a Canada-based clinical-stage biopharmaceutical company. The Company uses machine learning to develop targeted therapies. The Company's business is disease-specific drug discovery, optimization and pre-clinical development using a developed series of computer models. Its artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds that are projected to have a high probability of being developed from disease specific drug discovery through chemical optimization and preclinical testing. The CHEMSAS platform technology is focused on small molecules, and as a drug candidate discovery engine can be applied to any disease. The Company is engaged in developing molecules through the preclinical testing stage as commercial validation of the CHEMSAS platform. COTI-2 is the Company's small molecule activator of misfolded mutant p53 protein.

Officers and directors

John C. Drake Independent Chairman of the Board
Wayne R. Danter M.D. President, Chief Executive Officer, Chief Scientific Officer, Director
Gene Kelly Chief Financial Officer
Douglas S. Alexander Independent Director
Bruno C. Maruzzo Independent Director
Age: 61
Dave Sanderson Independent Director
Alison Silva Independent Director